12,400 Shares in Biohaven Ltd. (NYSE:BHVN) Acquired by SpiderRock Advisors LLC

SpiderRock Advisors LLC bought a new stake in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 12,400 shares of the company's stock, valued at approximately $620,000.

A number of other large investors also recently bought and sold shares of BHVN. Vanguard Group Inc. increased its stake in Biohaven by 280.5% during the 1st quarter. Vanguard Group Inc. now owns 6,308,853 shares of the company's stock worth $345,031,000 after buying an additional 4,650,702 shares in the last quarter. Oak Ridge Investments LLC boosted its holdings in shares of Biohaven by 197.6% during the 2nd quarter. Oak Ridge Investments LLC now owns 22,000 shares of the company's stock worth $764,000 after purchasing an additional 14,607 shares during the last quarter. CWM LLC lifted its position in Biohaven by 1,893.4% during the second quarter. CWM LLC now owns 14,552 shares of the company's stock worth $505,000 after buying an additional 13,822 shares in the last quarter. Bellevue Group AG grew its holdings in Biohaven by 7.0% in the 1st quarter. Bellevue Group AG now owns 1,150,000 shares of the company's stock valued at $62,894,000 after buying an additional 75,000 shares in the last quarter. Finally, Lord Abbett & CO. LLC acquired a new stake in shares of Biohaven in the 1st quarter worth $7,276,000. 88.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on BHVN shares. Robert W. Baird upped their price objective on shares of Biohaven from $58.00 to $60.00 and gave the company an "outperform" rating in a report on Monday, September 23rd. JPMorgan Chase & Co. lifted their target price on Biohaven from $55.00 to $68.00 and gave the company an "overweight" rating in a research report on Thursday, October 3rd. Leerink Partners increased their price target on Biohaven from $55.00 to $60.00 and gave the stock an "outperform" rating in a report on Monday, September 23rd. UBS Group lowered their target price on shares of Biohaven from $55.00 to $54.00 and set a "buy" rating for the company in a research note on Tuesday, August 13th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Biohaven in a research note on Wednesday, October 23rd. Thirteen equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $61.92.

Biohaven Stock Down 1.3 %

Shares of BHVN traded down $0.71 during trading on Monday, reaching $52.76. The company's stock had a trading volume of 325,249 shares, compared to its average volume of 1,138,578. Biohaven Ltd. has a twelve month low of $26.80 and a twelve month high of $62.21. The company has a market cap of $4.99 billion, a price-to-earnings ratio of -5.84 and a beta of 1.31. The company has a fifty day moving average of $47.04 and a two-hundred day moving average of $40.58.

Biohaven (NYSE:BHVN - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($3.64) EPS for the quarter, missing the consensus estimate of ($1.72) by ($1.92). As a group, equities analysts forecast that Biohaven Ltd. will post -8.81 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director John W. Childs bought 21,052 shares of the firm's stock in a transaction on Wednesday, October 2nd. The stock was purchased at an average price of $47.50 per share, with a total value of $999,970.00. Following the completion of the transaction, the director now directly owns 21,052 shares of the company's stock, valued at $999,970. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, Director John W. Childs purchased 21,052 shares of the firm's stock in a transaction that occurred on Wednesday, October 2nd. The shares were acquired at an average price of $47.50 per share, with a total value of $999,970.00. Following the purchase, the director now directly owns 21,052 shares in the company, valued at $999,970. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Gregory Bailey bought 5,000 shares of the company's stock in a transaction that occurred on Tuesday, September 24th. The shares were purchased at an average price of $44.19 per share, with a total value of $220,950.00. Following the transaction, the director now directly owns 1,620,071 shares in the company, valued at $71,590,937.49. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 16.00% of the company's stock.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.